These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 33051938)

  • 1. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
    Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
    Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys.
    Nagai Y; Oitate M; Shiozawa H; Ando O
    Xenobiotica; 2019 Sep; 49(9):1086-1096. PubMed ID: 30351177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
    Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
    Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
    Abuhelwa Z; Alloghbi A; Alqahtani A; Nagasaka M
    Drugs; 2022 Jun; 82(9):979-987. PubMed ID: 35759121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
    Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
    ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
    Swain SM; Nishino M; Lancaster LH; Li BT; Nicholson AG; Bartholmai BJ; Naidoo J; Schumacher-Wulf E; Shitara K; Tsurutani J; Conte P; Kato T; Andre F; Powell CA
    Cancer Treat Rev; 2022 May; 106():102378. PubMed ID: 35430509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
    Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
    ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
    Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
    Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
    Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
    Shitara K; Yamaguchi K; Muro K; Yasui H; Sakai D; Oshima T; Fujimura M; Sato Y; Yamazaki S; Wakabayashi T; Sugihara M; Kamio T; Shoji H
    Int J Clin Oncol; 2024 Jan; 29(1):27-35. PubMed ID: 37964066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
    Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
    Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
    Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
    JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
    Takahashi S; Karayama M; Takahashi M; Watanabe J; Minami H; Yamamoto N; Kinoshita I; Lin CC; Im YH; Achiwa I; Kamiyama E; Okuda Y; Lee C; Bang YJ
    Clin Cancer Res; 2021 Nov; 27(21):5771-5780. PubMed ID: 34426442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
    N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
    Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
    Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
    Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
    Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
    N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.